Doseology Sciences Inc.

OTC: DOSEF · Healthcare · Biotechnology

Canadian filerHQ Kelowna, BCReports USD

#1094 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

40D

FH 44DQ —GM 39SS 16

v0.1 · 45/100 weight · provisional

↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

$58.6k

Rev growth YoY (TTM)

+75.7%

Net income (FY)

-$235.7k

Employees

Market cap

$504.5k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$22.4k31.3k CAD2025

Net income-$235.7k-328.9k CAD2025

Operating income-$248.2k-346.4k CAD2025

Total assets$803.1k1.1M CAD2025

Liabilities$69.0k94.1k CAD2025

Equity$1.0M1.4M CAD2025

Revenue trend

FY2021 – FY2025 · USD

FY21

$12.7k

FY22

$32.2k

FY23

$72.7k

FY24

$22.4k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Doseology Sciences Inc. booked $22.4k in FY2025 revenue, contracting 69% year over year — slower than 86% of Healthcare companies we track, at a -1052.2% net margin.

Peers · Healthcare

BiomX Inc.——CENTR Brands Corp.17D Therapeutic Solutions International, Inc.——NovelStem International Corp.37D

Key facts

CEOChristopher Jackson

SectorHealthcare

IndustryBiotechnology

HeadquartersKelowna, BC

ExchangeOTC: DOSEF

Employees3

IPO date2022-05-11

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.